Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;24(5):409-441.
doi: 10.1007/s11864-023-01061-8. Epub 2023 Apr 3.

"Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect

Yuxin An  1 , Xin Jin  2 , Hongkai Zhang  3 , Meng Zhang  1 , Sadhana Mahara  1 , Wenyi Lu  4 , Mingfeng Zhao  5
Affiliations
Review

"Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect

Yuxin An et al. Curr Treat Options Oncol. 2023 May.

Abstract

Chimeric antigen receptor (CAR) cell therapy offers patients with hematological malignancies a new therapeutic option. Traditionally, autologous T cells are used to generate CAR designed T cells for each patient. However, this method has several drawbacks, the development of allogeneic CAR cell therapy would be a promising breakthrough that could address several of these limitations. From the clinical trials that have published data, the efficacy of allogeneic CAR cell therapy did not meet the expectations. Because of the host-versus-graft (HvG) effect, allogeneic CAR cells are eliminated by the host, resulting in short-term persistence of allogeneic CAR cells and poor efficacy. It is critical to solve the HvG effect of allogeneic CAR cells. The current commonly used methods are suppressing the host's immune system, using HLA-matched homozygous donors, reducing the expression of HLA, targeting alloreactive lymphocytes and eliminating anti-CAR activities. In this review, we will focus on the HvG effect of the "off-the-shelf" allogeneic CAR cell therapy, especially its mechanism and current methods to solve this problem and summarize relevant clinical trial data.

Keywords: Allogeneic CAR; CAR cell therapy; Chimeric antigen receptor (CAR); Host-versus-graft effect.

PubMed Disclaimer

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325–38. https://doi.org/10.1182/bloodadvances.2020001466 . - DOI - PubMed - PMC
    1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–44. https://doi.org/10.1056/NEJMoa1707447 . - DOI - PubMed - PMC
    1. Zhang M, Jin X, Sun R, Xiong X, Wang J, Xie D, et al. Optimization of metabolism to improve efficacy during CAR-T cell manufacturing. J Transl Med. 2021;19(1):499. https://doi.org/10.1186/s12967-021-03165-x . - DOI - PubMed - PMC
    1. Khurana A, Lin Y. Allogeneic Chimeric antigen receptor therapy in lymphoma. Curr Treat Options Oncol. 2022;23(2):171–87. https://doi.org/10.1007/s11864-021-00920-6 . - DOI - PubMed - PMC
    1. Poehlein CH, Haley DP, Walker EB, Fox BA. Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunol. 2009;39(11):3121–33. https://doi.org/10.1002/eji.200939453 . - DOI - PubMed - PMC

Publication types

MeSH terms

LinkOut - more resources